retatrutide phase 3 triumph 🚨 HOT OFF THE PRESS: data has arrived — and the obesity medicine world is paying attention. In Lilly's TRIUMPH-1 trial, participants receiving the highest dose achieved an average retatrutide 3 months A summary

A widely held assumption is that Chinese firms could file for DCGI (Drugs Controller General of India) approval and disrupt the Indian market within 12 to 18 months

Peter Strouhal, a medical director at Alliance Medical Ltd in the UK and lead author of the new study, said in a statement: "We noticed unusual uptake in one of our patients on a GLP-1 agonist, which prompted a wider review across our network." He added: We found that these altered patterns are increasingly common, yet there is currently no national or international guidance in the UK addressing this emerging issue

Rotate the injection sites to prevent tissue damage or lipodystrophy

While oxidative stress is elevated in obesity and metabolic syndrome, supplementing antioxidants doesn't reverse the hormonal drivers of weight gain (leptin resistance, elevated ghrelin, insulin resistance)

When activated with GLP-1r, GIP seems to potentiate not only the weight loss mechanism of the incretin but also the glucose lowering effects [13]

Antioxidants help protect cells from oxidative damage